Quipt Home Medical Corp Stock Price, News & Analysis

Quipt Home Medical Corp. (NASDAQ:QIPT) has acquired NorCal Respiratory, enhancing its presence in California with three new locations. This acquisition is expected to add approximately $3.2 million in annualized revenues and $650,000 to Adjusted EBITDA post-integration. Quipt's active patient count will increase to around 184,000, supported by a network of over 19,600 physicians. The deal, valued at approximately $3.1 million in cash, aligns with Quipt’s growth strategy focused on respiratory care, particularly in regions with a high prevalence of COPD.

Quipt Home Medical Corp. (NASDAQ:QIPT) announced its preliminary inclusion in the Russell Microcap Index, effective June 27, 2022. This milestone is expected to enhance the Company’s visibility within the investment community as it aims to grow in the home respiratory care market. CEO Greg Crawford highlighted that this membership reflects Quipt's substantial growth and strategic positioning. The Russell Microcap Index is recognized by investment managers, with $12 trillion in assets benchmarked against it, potentially driving investment towards Quipt.

Quipt Home Medical Corp. (NASDAQ:QIPT) reported a 38% revenue growth year-over-year, reaching $33.6 million for Q2 2022, and a 31% increase in adjusted EBITDA of $7.0 million. The company's net income turned positive at $5 million compared to a loss of $12.5 million a year earlier. With a 77% recurring revenue rate and a solid patient base growth of 37%, management projects an annual run-rate revenue of $180-$190 million by the end of 2022.

Additionally, several acquisitions have bolstered its market presence.

Quipt Home Medical Corp. (NASDAQ: QIPT) will host its Fiscal Q2 2022 earnings conference call on May 17, 2022, at 10:00 a.m. (EST). This event highlights the company's commitment to transparency and investor engagement. The call will be accessible via audio webcast on their investor website. Quipt focuses on providing in-home monitoring and disease management services for chronic conditions, aiming to expand their service offerings while increasing annual revenue per patient. For more details, visit their website.

Quipt Home Medical Corp. has announced a significant national insurance contract with one of the top five health insurers in the U.S., marking a pivotal moment in its growth strategy. This contract facilitates entry into new states, enhancing their operational reach and patient access. CEO Greg Crawford emphasized the contract's potential for accelerating their expansion and capturing patient volume, while also indicating plans to pursue additional national contracts to further strengthen their business model and service offerings.

Quipt Home Medical Corp. (NASDAQ:QIPT) has acquired Good Night Medical, enhancing its operational footprint in seven U.S. states. The $7 million cash transaction is projected to add $7.5 million in annualized revenues and $1.5 million in adjusted EBITDA (20% margin) post-integration. This acquisition brings over 10,000 active patients, contributing to Quipt's total of approximately 180,000. The move allows Quipt to expand its market presence in states with high COPD prevalence and leverage synergistic opportunities across existing operations.

Quipt Home Medical Corp. (NASDAQ: QIPT) announced its participation in the Sidoti Virtual Investor Conference on March 23-24, 2022. The management team will host a webcasted presentation at 9:15 AM EST on March 23. The live event will be available on the company's investor website and can be replayed afterward. CEO Greg Crawford highlighted the company's growth strategy, focusing on operational execution and integration of acquired assets, with plans for continued expansion through acquisitions. The company aims to enhance shareholder value by improving in-home monitoring services for chronic conditions.

Quipt Home Medical (NASDAQ:QIPT) reported a 30% increase in revenue for Q1 2022, reaching $29.5 million, compared to $22.8 million in Q1 2021. Adjusted EBITDA grew 16% year-over-year, totaling $6 million with a margin of 20.3%. Recurring revenue comprised 77% of total revenue. The company has a backlog of 8,000 patients awaiting sleep device setups, anticipating a revenue lift later in 2022. Cash flow from operations surged 90% year-over-year, reaching $5.3 million. The outlook for 2022 remains strong, with projected annual revenues of $180-$190 million.

Quipt Home Medical Corp. (NASDAQ: QIPT) announced the appointment of Brian J. Wessel as an Independent Director and Chair of the Audit Committee. With over 34 years of experience in global client service and financial expertise, Wessel's prior role as a senior partner at Ernst & Young enhances Quipt's strategic growth plans. The board now comprises four members, three of whom are independent. Additionally, Quipt received confirmation of compliance with Nasdaq's Listing Rules, following its recent filing, solidifying its position in the market.